Hakozaki, Taiki
Hosomi, Yukio http://orcid.org/0000-0002-3849-5905
Shimizu, Akihiro
Kitadai, Rui
Mirokuji, Kie
Okuma, Yusuke
Article History
Received: 25 February 2020
Accepted: 8 May 2020
First Online: 27 May 2020
Compliance with ethical standards
:
: YH has received personal fees from AstraZeneca, Eli Lilly Japan, Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, Kyowa Kirin, and CSL Behring, outside the submitted work. YO has received personal fees from Chugai Pharmaceutical and Takeda Oncology, outside the submitted work. No other potential conflicts of interest were reported.
: The study protocol was approved by the Ethics Committee of the Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital (approval number: 2342) and conducted in accordance with the tenets of the Declaration of Helsinki.
: The datasets used and analyzed during the present study are available from the corresponding author on reasonable request.
: Presented in part at European Society for Medical Oncology Asia Congress 2019, Singapore, November 23, 2019.